| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Profit before tax | -0.7 | -0.9 |
| Net income | -0.7 | -0.9 |
| EPS (diluted, $ a share) | $-0.37 | $-0.47 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, OTC: PTIX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Protagenic Therapeutics, Inc.\new: key numbers
- Share price
- $0.4500Close, Nov 16
- Market cap
- $815K
- Shares outstanding
- 1.81MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Protagenic Therapeutics, Inc.\new
All →Protagenic Therapeutics, Inc.\new Capital Raise of $1.5M
Protagenic Therapeutics entered into a securities purchase agreement for a private placement offering of common stock and warrants, raising $1.5 million in initial gross proceeds. The company may raise up to $5 million in total through subsequent closings and the exercise of milestone-linked warrants. Proceeds will be used to fund IND-enabling activities and the initiation of a Phase 1/2a clinical trial for PT00114 in Generalized Anxiety Disorder.
- Value
- $1.5M
Protagenic Therapeutics, Inc.\new Debt Financing Update with Patness LLC
Protagenic Therapeutics issued a $250,000 promissory note to Patness LLC bearing 1.0% annual interest. The debt is due upon the earlier of a future equity capital raise of at least $1 million or 180 days from the issuance date. Interest is forgiven if the principal is repaid within 365 days.
- Counterparty
- Patness LLC
- Term
- 180 days